Virdante Pharmaceuticals, Inc. Lands $30M in A Round to Combat Inflammation  
10/29/2009 7:31:25 AM

Bookmark and Share -- Virdante Pharmaceuticals is expanding development of its anti-inflammatory drugs with a second closing of what is now a $30 million Series A round of venture capital, the company’s CEO, John Ripple, said. The Cambridge, MA-based biotech startup has found potential ways to boost the anti-inflammatory effects of conventional antibody drugs and to create novel therapies to treat diseases in which the immune system attacks healthy tissue.